| 4.27 -0.36 (-7.78%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.2  |
1-year : | 6.99 |
| Resists | First : | 5.31 |
Second : | 5.98 |
| Pivot price | 4.96  |
|||
| Supports | First : | 4.21 |
Second : | 3.5 |
| MAs | MA(5) : | 4.54 |
MA(20) : | 5.04 |
| MA(100) : | 4.45 |
MA(250) : | 5.93 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 12.1 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 12.68 | Low : | 1.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TSVT ] has closed above bottom band by 4.1%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.75 - 4.78 | 4.78 - 4.8 |
| Low: | 4.14 - 4.17 | 4.17 - 4.2 |
| Close: | 4.22 - 4.27 | 4.27 - 4.32 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Wed, 17 Apr 2024
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why - Yahoo Finance
Wed, 17 Apr 2024
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why - Zacks Investment Research
Wed, 03 Apr 2024
2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround (NASDAQ:TSVT) - Seeking Alpha
Tue, 19 Mar 2024
Should You Buy 2Seventy Bio Inc (TSVT) Stock Tuesday Morning? - InvestorsObserver
Fri, 15 Mar 2024
Premarket Mover: 2Seventy Bio Inc (TSVT) Up 8.59% - InvestorsObserver
Wed, 06 Mar 2024
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 98.5 (%) |
| Shares Short | 6,810 (K) |
| Shares Short P.Month | 5,590 (K) |
| EPS | -4.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.03 |
| Profit Margin | -216.8 % |
| Operating Margin | -560.5 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -77 % |
| Qtrly Rev. Growth | -81 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.95 |
| EBITDA (p.s.) | -4.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -167 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | 0.84 |
| Price to Sales | 2.18 |
| Price to Cash Flow | -1.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|